Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
OPTIMER PHARMACEUTICALS INC (OPTR)
|
Add to portfolio |
|
|
|
| Price: |
$14.44
| | Metrics |
| OS: |
48.9
|
M
| |
-94
|
% ROE
|
| Market cap: |
$706
|
M
| |
|
|
|
Net cash:
|
$77.5
|
M
| |
$1.59
|
per share
|
|
EV:
|
$629
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($93.2)
|
M
| |
|
|
|
EBIT
|
($94.0)
|
M
| |
|
|
| EPS |
($1.74)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 101.5 | 145.0 | 1.5 | 0.9 | 1.0 | 0.8 | 0.9 | 2.1 |
| Revenue growth | -30.0% | 9693.4% | 65.8% | -12.8% | 33.4% | -17.8% | -56.5% | -99.8% |
| Cost of goods sold | 5.5 | 1.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 96.0 | 143.5 | 1.5 | 0.9 | 1.0 | 0.8 | 0.9 | 2.1 |
| Gross margin | 94.6% | 98.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | | | 17.6 | 9.1 | | | | |
| Sales and marketing | 23.2 | 6.6 | | | 1.3 | 2.0 | | |
| Research and development | 45.2 | 43.1 | 32.8 | 34.4 | | | | |
| General and administrative | 112.0 | 80.6 | | | 6.7 | 5.4 | 3.5 | 2.8 |
| EBIT | -68.9 | 5.6 | -48.9 | -42.6 | -37.1 | -48.2 | -13.1 | -7.7 |
| EBIT margin | -67.9% | 3.9% | -3301.1% | -4772.1% | -3629.8% | -6283.0% | -1400.8% | -357.9% |
| Pre-tax income | -36.6 | 7.9 | -47.3 | 0.0 | -35.6 | -46.1 | -11.9 | -7.4 |
| Income taxes | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.8% | 0.3% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -37.0 | 7.8 | -47.3 | -42.1 | -35.6 | -46.1 | -12.2 | -7.7 |
| Net margin | -36.4% | 5.4% | -3197.8% | -4715.5% | -3477.2% | -6014.2% | -1310.8% | -357.2% |
| |
| Diluted EPS | ($0.78) | $0.17 | ($1.25) | ($1.30) | ($1.24) | $0.00 | ($4.81) | ($3.22) |
| Shares outstanding (diluted) | 47.3 | 46.5 | 37.8 | 32.5 | 28.7 | 21,715.3 | 2.5 | 2.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|